Amgen Inc. Revenue from Contract with Customer, Including Assessed Tax
Amgen Inc. (AMGN) reported Revenue from Contract with Customer, Including Assessed Tax of $26.32 billion for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-09.
Discontinued › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2023-02-09
- Amgen Inc. revenue from contract with customer, including assessed tax for fiscal 2022 was $26.32B, a 1.32% increase from fiscal 2021.
- Amgen Inc. revenue from contract with customer, including assessed tax for fiscal 2021 was $25.98B, a 2.18% increase from fiscal 2020.
- Amgen Inc. revenue from contract with customer, including assessed tax for fiscal 2020 was $25.42B, a 8.83% increase from fiscal 2019.
- Amgen Inc. revenue from contract with customer, including assessed tax for fiscal 2019 was $23.36B, a 1.62% decline from fiscal 2018.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 12 month |
|---|---|
| 2022-12-31 | $26.32B 10-K · filed 2023-02-09 |
| 2021-12-31 | $25.98B 10-K · filed 2023-02-09 |
| 2020-12-31 | $25.42B 10-K · filed 2023-02-09 |
| 2019-12-31 | $23.36B 10-K · filed 2022-02-16 |
| 2018-12-31 | $23.75B 10-K · filed 2021-02-09 |
| 2017-12-31 | $22.85B 10-K · filed 2020-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |